Genetically engineered vaccinia viruses
The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
1. A vaccinia virus comprising a polynucleotide encoding interleukin-7(IL-7); and a polynucleotide encoding interleukin-12(IL-12), wherein the vaccinia virus is deficient in the function of vaccinia virus growth factor (VGF) or deficient in the function of O1L, and wherein the vaccinia virus is oncolytic against human cancer cells.
2. The vaccinia virus according to claim 1 , wherein the vaccinia virus is deficient in the function of VGF.
3. The vaccinia virus according to claim 1 , wherein the vaccinia virus is deficient in the function of O1L.
4. The vaccinia virus according to claim 1 , wherein the vaccinia virus is deficient in the functions of VGF and O1L.
5. The vaccinia virus according to claim 1 , wherein the vaccinia virus has a deletion in the short consensus repeat (SCR) domains in the B5R extracellular region.
6. The vaccinia virus according to claim 1 , wherein the vaccinia virus is deficient in the functions of VGF and O1L and has a deletion in the SCR domains in the B5R extracellular region.
7. The vaccinia virus according to claim 1 , wherein the vaccinia virus is a LC16mO strain.
8. The vaccinia virus according to claim 1 , wherein the vaccinia virus is deficient in the functions of VGF and O1L and has a deletion in the SCR domains in the B5R extracellular region and is a LC16mO strain.
9. A pharmaceutical composition comprising a vaccinia virus according to claim 1 and a pharmaceutically acceptable excipient.
10. The pharmaceutical composition according to claim 9 , wherein the vaccinia virus is deficient in the function of VGF.
11. The pharmaceutical composition according to claim 9 , wherein the vaccinia virus is deficient in the function of O1L.
12. The pharmaceutical composition according to claim 9 , wherein the vaccinia virus is deficient in the functions of VGF and O1L.
13. The pharmaceutical composition according to claim 9 , wherein the vaccinia virus has a deletion in the SCR domains in the B5R extracellular region.
14. The pharmaceutical composition according to claim 9 , wherein the vaccinia virus is deficient in the functions of VGF and O1L and has a deletion in the SCR domains in the B5R extracellular region.
15. The pharmaceutical composition according to claim 9 , wherein the vaccinia virus is a LC16mO strain.
16. The pharmaceutical composition according to claim 9 , wherein the vaccinia virus is deficient in the functions of VGF and O1L and has a deletion in the SCR domains in the B5R extracellular region and is a LC16mO strain.
17. A combination kit comprising: a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12, wherein the vaccinia viruses are deficient in the function of VGF or deficient in the function of O1L, and wherein the vaccinia viruses in combination are oncolytic against human cancer cells.
18. The kit according to claim 17 , wherein the vaccinia viruses are deficient in the function of VGF.
19. The kit according to claim 17 , wherein the vaccinia viruses are deficient in the function of O1L.
20. The kit according to claim 17 , wherein the vaccinia viruses are deficient in the functions of VGF and O1L.
21. The kit according to claim 17 , wherein the vaccinia viruses have a deletion in the SCR domains in the B5R extracellular region.
22. The kit according to claim 17 , wherein the vaccinia viruses are deficient in the functions of VGF and O1L and has a deletion in the SCR domains in the B5R extracellular region.
23. The kit according to claim 17 , wherein the vaccinia viruses are a LC16mO strain.
24. The kit according to claim 17 , wherein the vaccinia viruses are deficient in the functions of VGF and O1L and has a deletion in the SCR domains in the B5R extracellular region and is a LC16mO strain.
25. The kit according to claim 17 , further comprising a pharmaceutically acceptable excipient.